$-2.58 EPS Expected for Intercept Pharmaceuticals, Inc. (ICPT)

October 14, 2018 - By Adrian Erickson

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) LogoInvestors sentiment increased to 1.27 in Q2 2018. Its up 0.12, from 1.15 in 2018Q1. It increased, as 15 investors sold Intercept Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 45 raised stakes. 19.65 million shares or 4.20% more from 18.85 million shares in 2018Q1 were reported.
California State Teachers Retirement holds 0.01% or 33,523 shares. Birchview L P reported 4,300 shares stake. Hudock Grp Limited Liability Co stated it has 50 shares or 0% of all its holdings. Exane Derivatives accumulated 0% or 7 shares. Morgan Stanley has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Eulav Asset Mngmt has invested 0.31% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Fifth Third National Bank & Trust accumulated 736 shares or 0% of the stock. 10,396 are owned by Ubs Asset Americas. Fisher Asset Management Ltd Liability owns 44,587 shares for 0% of their portfolio. Us Comml Bank De, a Minnesota-based fund reported 1,775 shares. Profund Advsr Ltd Limited Liability Company reported 6,499 shares stake. California Public Employees Retirement System reported 27,000 shares. Moreover, Regal Investment Advisors Limited Liability Com has 0.62% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). National Bank Of Mellon has 89,885 shares. Great West Life Assurance Can reported 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Analysts expect Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report $-2.58 EPS on November, 7.They anticipate $0.31 EPS change or 10.73 % from last quarter’s $-2.89 EPS. After having $-2.58 EPS previously, Intercept Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.19% or $3.21 during the last trading session, reaching $103.73. About 375,077 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has risen 19.09% since October 14, 2017 and is uptrending. It has outperformed by 3.47% the S&P500.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 7 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Intercept Pharmaceuticals had 9 analyst reports since April 17, 2018 according to SRatingsIntel. Raymond James downgraded Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Tuesday, October 2. Raymond James has “Outperform” rating and $141 target. The firm has “Sector Perform” rating given on Wednesday, August 15 by RBC Capital Markets. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Outperform” rating given on Tuesday, April 17 by Wedbush. Laidlaw downgraded the shares of ICPT in report on Friday, August 3 to “Hold” rating. Wedbush maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Monday, August 6. Wedbush has “Outperform” rating and $217 target. The company was upgraded on Monday, August 6 by Goldman Sachs. The firm earned “Overweight” rating on Monday, October 1 by Cantor Fitzgerald.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $3.07 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on October 01, 2018, also Fool.com with their article: “Is Viking Therapeutics the Best NASH Stock to Buy Now?” published on September 20, 2018, Seekingalpha.com published: “CymaBay, GenKyoTex, And Intercept In PBC: The Clinical Differentiation” on October 10, 2018. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: Investorplace.com and their article: “5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH” published on September 26, 2018 as well as Fool.com‘s news article titled: “3 Small Biotech Stocks at 52-Week Highs — Are They Buys?” with publication date: October 03, 2018.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News